Technical Analysis for CTMX - CytomX Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
20 DMA Resistance | Bearish | -2.42% | |
Calm After Storm | Range Contraction | -2.42% | |
Wide Bands | Range Expansion | -2.42% | |
Fell Below 20 DMA | Bearish | -1.94% | |
Calm After Storm | Range Contraction | -1.94% | |
Wide Bands | Range Expansion | -1.94% | |
Down 3 Days in a Row | Weakness | -1.94% | |
MACD Bearish Signal Line Cross | Bearish | -3.81% |
Alert | Time |
---|---|
Down 5% | about 17 hours ago |
2x Volume Pace | about 18 hours ago |
1.5x Volume Pace | about 18 hours ago |
Down 3% | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/11/2024
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Immunogen Monoclonal Antibody Therapy Oncology Focused Biopharmaceutical
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Immunogen Monoclonal Antibody Therapy Oncology Focused Biopharmaceutical
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.855 |
52 Week Low | 1.04 |
Average Volume | 940,686 |
200-Day Moving Average | 1.55 |
50-Day Moving Average | 1.81 |
20-Day Moving Average | 2.18 |
10-Day Moving Average | 2.34 |
Average True Range | 0.21 |
RSI (14) | 47.92 |
ADX | 30.32 |
+DI | 22.35 |
-DI | 28.24 |
Chandelier Exit (Long, 3 ATRs) | 2.24 |
Chandelier Exit (Short, 3 ATRs) | 2.05 |
Upper Bollinger Bands | 3.07 |
Lower Bollinger Band | 1.29 |
Percent B (%b) | 0.41 |
BandWidth | 82.00 |
MACD Line | 0.12 |
MACD Signal Line | 0.19 |
MACD Histogram | -0.0711 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.24 | ||||
Resistance 3 (R3) | 2.24 | 2.17 | 2.20 | ||
Resistance 2 (R2) | 2.17 | 2.11 | 2.17 | 2.19 | |
Resistance 1 (R1) | 2.10 | 2.08 | 2.06 | 2.09 | 2.18 |
Pivot Point | 2.03 | 2.03 | 2.01 | 2.02 | 2.03 |
Support 1 (S1) | 1.95 | 1.97 | 1.92 | 1.95 | 1.86 |
Support 2 (S2) | 1.88 | 1.94 | 1.88 | 1.85 | |
Support 3 (S3) | 1.81 | 1.88 | 1.84 | ||
Support 4 (S4) | 1.80 |